Swedish Bone Cement Maker Touts Recent Scientific Article’s Findings

Officials from Bonesupport AB, a Sweden-based developer of injectable bone substitutes for orthopedic trauma, bone infections and instrument augmentation related to orthopedic surgery, claim that a recent article summarizing available published and presented data for composite products containing calcium sulphate and hydroxyapatite, extensively refers to preclinical studies and clinical applications published about the company’s Cerament bone void filler.

The article was published in the latest issue of the journal Expert Review of Medical Devices.

The authors conclude that the preclinical and clinical data to date support the safety, efficacy and bone remodeling performance of Cerament, the company reported. Officials at the Lund, Sweden-based firm claim that the papers authors found good clinical outcome in various applications such as osteotomies, cyst and defect filling, skull deformations, vertebroplasty and diabetic foot infections, with healing occurring in both normal and osteoporotic bone.

“Bone is the second most transplanted tissue, after blood, and the current standard of care is autografts which is associated with high donor site morbidity,” said Prof. Ming Hao Zheng, lead researcher in this study. “There is a significant need for a superior injectable bone substitute and Cerament offers good clinical outcomes in a wide range of applications. Moreover, the drug release capability, in addition to the osteoconductivity of Cerament, offers a promising breakthrough for treatment of deep bone infections and joint prosthetic infections.”

Scientific research into Cerament has been going on for more than 10 years and has spanned 50 studies, “the most for any injectable bone substitute on the market,” claims Lloyd Diamond, CEO of Bonesupport.

“Our success as a next-generation bone graft substitute will be measured by the difference we can make in the lives of patients fighting serious disease,” Diamond said. “We are pleased to see the positive outcomes validated once again in this comprehensive study.”

Cerament is an injectable, synthetic bone substitute that mimics the properties of cancellous bone, allows for controlled resorption to support future bone ingrowth and is injectable under local anesthesia for minimally invasive surgery.

Cerament-G is the first CE-marked injectable gentamicin antibiotic eluting ceramic bone graft substitute. It is indicated to promote and protect bone healing in the management of osteomyelitis, (bone infections) in CE marked countries. Cerament-G is not available in the United States.

The original Cerament is commercially available in the United States and Europe. Bonesupport, founded in 1999, claims that more than 6,000 patients have been treated with Cerament.